Literature DB >> 7388756

Sustained-release properties of microencapsulated mitomycin C with ethylcellulose infused into the renal artery of the dog.

T Kato, R Nemoto, H Mori, I Kumagai.   

Abstract

Mitomycin C (MMC) was microencapsulated with ethylcellulose. The microcapsules contained, on average, 80% of biologically active MMC and had a sustained-release property. The mean particle size was 224 micrometers so that the microcapsules were readily infused into a canine kidney through arterial catheterization. Ex vivo infusion demonstrated that the microcapsules lodged in the small arteries, mainly at the cortico-medullary junction, and released concentrated MMC into the surrounding tissue. In vivo experiments revealed that the canine kidneys infused with the microcapsules retained active MMC for more than 6 hours and showed extensive necrosis five days after the infusion. The kidneyks infused with nonencapsulated MMC rapidly excreted MMC and showed mild histologic changes. The blood level of MMC released from the intrarenal microcapsules was markedly reduced as compared with control levels. The results suggest that the potential therapeutic effect of intraarterial infusion of MMC microcapsules is a function of embolization and prolonged drug action, and that selective infusion of MMC microcapsules into tumor-supplying arteries could facilitate intensive topical chemotherapy with minimum systemic side-effects.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7388756     DOI: 10.1002/1097-0142(19800701)46:1<14::aid-cncr2820460103>3.0.co;2-n

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  10 in total

1.  Toxicity of magnetic albumin microspheres bearing adriamycin.

Authors:  J Ma; D Chen; Y Tian; K Tao
Journal:  J Tongji Med Univ       Date:  2000

2.  (D, L) polylactide microspheres as embolic agent. A preliminary study.

Authors:  P Flandroy; C Grandfils; J Collignon; A Thibaut; N Nihant; S Barbette; R Jerome; P Teyssie
Journal:  Neuroradiology       Date:  1990       Impact factor: 2.804

3.  Antitumor effect of arterial administration of a medium-chain triglyceride solution of an angiogenesis inhibitor, TNP-470, in rabbits bearing VX-2 carcinoma.

Authors:  S Yanai; H Okada; K Saito; Y Kuge; M Misaki; Y Ogawa; H Toguchi
Journal:  Pharm Res       Date:  1995-05       Impact factor: 4.200

4.  A modified method for preparation of adriamycin carried by magnetic albumin microspheres.

Authors:  J Ma; D Chen; Y Tian
Journal:  J Tongji Med Univ       Date:  2001

5.  Magnetic microcapsules for targeted delivery of anticancer drugs.

Authors:  T Kato; R Nemoto; H Mori; R Abe; K Unno; A Goto; H Murota; M Harada; M Homma
Journal:  Appl Biochem Biotechnol       Date:  1984       Impact factor: 2.926

6.  Mitomycin-induced hemolytic uremic kidney. An experimental model in the rat.

Authors:  V Cattell
Journal:  Am J Pathol       Date:  1985-10       Impact factor: 4.307

7.  Continued in vitro and in vivo release of an antitumor drug from albumin microspheres.

Authors:  S Fujimoto; F Endoh; Y Kitsukawa; K Okui; Y Morimoto; K Sugibayashi; A Miyakawa; H Suzuki
Journal:  Experientia       Date:  1983-08-15

8.  Systemic blood levels after intra-arterial administration of microencapsulated mitomycin C in cancer patients.

Authors:  G Milano; J L Boublil; J N Bruneton; J Bourry; N Renee; A Thyss; P Roux; M Namer
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1985 Jul-Sep       Impact factor: 2.441

Review 9.  Hepatic arterial chemotherapy for metastatic colorectal carcinoma.

Authors:  P G de Takats; D J Kerr; C J Poole; H W Warren; C S McArdle
Journal:  Br J Cancer       Date:  1994-02       Impact factor: 7.640

10.  Implantation treatment method of slow release anticancer doxorubicin containing hydroxyapatite (DOX-HAP) complex. A basic study of a new treatment for hepatic cancer.

Authors:  K Kunieda; T Seki; S Nakatani; M Wakabayashi; T Shiro; K Inoue; M Sougawa; R Kimura; K Harada
Journal:  Br J Cancer       Date:  1993-04       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.